Coming off what it’s described as its “best year ever,” the continuous glucose monitoring provider Dexcom is now looking to expand its work among people with Type 2 diabetes in a new, wider ...
Medical device maker DexCom announced Tuesday that the company has received a de novo clearance from the FDA to sell its latest continuous glucose monitoring system — the G6 — that requires no ...
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the FDA has cleared the next-generation ...
San Diego’s Dexcom posted a 30 percent jump in revenue for the March quarter as it prepares for a major launch of its next generation continuous glucose monitors that no longer requires finger pricks ...
In addition to the G6, which will either require no fingerstick calibration or just one calibration at launch, depending on the company’s ultimate FDA strategy, Dexcom is planning to complete ...
DexCom ($DXCM) made a big splash last quarter when it launched a marketing campaign featuring teen pop idol Nick Jonas, who has Type 1 diabetes. The move to address ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback